Evidence map›Paper›PMID 30368972›Full record

ArticleAdvanced materials (Deerfield Beach, Fla.)2018

Nanoparticle-Laden Macrophages for Tumor-Tropic Drug Delivery.

Weizhong Zhang, Mengzhe Wang, Wei Tang, Ru Wen, Shiyi Zhou, Chaebin Lee, Hui Wang, Wen Jiang, Ian Michael Delahunty, Zipeng Zhen and 7 more

Erratum issuedOpen access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced materials (Deerfield Beach, Fla.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 80 papers.

0numbers the graph read from it
0cells of the map it votes in
80citing papers in PubMed
8.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

80 citing papers in PubMed, 202 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review

20 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors at 2 institutions in 1 country.

Weizhong ZhangDepartment of Chemistry, University of Georgia, Athens, GA, 30602, USA.
Mengzhe WangDepartment of Radiology and Biomedical Research Imaging Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.
Wei TangDepartment of Chemistry, University of Georgia, Athens, GA, 30602, USA.
Ru WenDepartment of Chemistry, University of Georgia, Athens, GA, 30602, USA.
Shiyi ZhouDepartment of Chemistry, University of Georgia, Athens, GA, 30602, USA.
Chaebin LeeDepartment of Chemistry, University of Georgia, Athens, GA, 30602, USA.
Hui WangDepartment of Radiology and Biomedical Research Imaging Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.
Wen JiangDepartment of Chemistry, University of Georgia, Athens, GA, 30602, USA.
Ian Michael DelahuntyDepartment of Chemistry, University of Georgia, Athens, GA, 30602, USA.
Zipeng ZhenDepartment of Chemistry, University of Georgia, Athens, GA, 30602, USA.
Hongmin ChenDepartment of Chemistry, University of Georgia, Athens, GA, 30602, USA.
Matthew ChapmanDepartment of Chemistry, University of Georgia, Athens, GA, 30602, USA.
Zhanhong WuDepartment of Radiology and Biomedical Research Imaging Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.
Elizabeth W HowerthDepartment of Pathology, College of Veterinary Medicine, University of Georgia, Athens, GA, 30602, USA.
Houjian CaiDepartment of Pharmaceutical and Biomedical Sciences, College of Pharmacy, University of Georgia Athens, Athens, GA, 30602, USA.
Zibo LiDepartment of Radiology and Biomedical Research Imaging Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.
Jin XieDepartment of Chemistry, University of Georgia, Athens, GA, 30602, USA.ORCID https://orcid.org/0000-0002-8915-6233
University of Georgia · USUniversity of North Carolina at Chapel Hill · US

Funding

Heparan Sulfate in Prostate CancerU01CA225784 · NCI · UNIVERSITY OF SOUTH FLORIDA · PI CAI, HOUJIAN, WANG, LIANCHUN · 2018 to 2023
$2.6M
Combined Nanoparticle and Neural Stem Cell Therapies in a Pig Model of StrokeR01NS093314 · NINDS · UNIVERSITY OF GEORGIA · PI WEST, FRANKLIN D · 2015 to 2019
$2.4M
Nanoscintillator-based X-ray sensitizers to enable efficient NSCLC treatment with X-ray irradiationR01EB022596 · NIBIB · UNIVERSITY OF GEORGIA · PI XIE, JIN · 2017 to 2020
$1.9M
Targeting myristoylation of Src family kinases for inhibition of prostate tumorigenesisR01CA172495 · NCI · UNIVERSITY OF GEORGIA · PI CAI, HOUJIAN · 2013 to 2017
$1.7M
Congressionally Directed Medical Research Programs CA140666National Science Foundation NSF1552617NCI NIH HHS R01 CA172495NCI NIH HHS U01 CA225784NIBIB NIH HHS R01 EB022596NIH HHS R01EB022596NIH HHS R01NS093314NINDS NIH HHS R01 NS093314
6 · The paper itself

Abstract

Macrophages hold great potential in cancer drug delivery because they can sense chemotactic cues and home to tumors with high efficiency. However, it remains a challenge to load large amounts of therapeutics into macrophages without compromising cell functions. This study reports a silica-based drug nanocapsule approach to solve this issue. The nanocapsule consists of a drug-silica complex filling and a solid silica sheath, and it is designed to minimally release drug molecules in the early hours of cell entry. While taken up by macrophages at high rates, the nanocapsules minimally affect cell migration in the first 6-12 h, buying time for macrophages to home to tumors and release drugs in situ. In particular, it is shown that doxorubicin (Dox) as a representative drug can be loaded into macrophages up to 16.6 pg per cell using this approach. When tested in a U87MG xenograft model, intravenously (i.v.) injected Dox-laden macrophages show comparable tumor accumulation as untreated macrophages. Therapy leads to efficient tumor growth suppression, while causing little systematic toxicity. This study suggests a new cell platform for selective drug delivery, which can be readily extended to the treatment of other types of diseases.

Indexed as

AnimalsCell Line, TumorCell SurvivalDoxorubicinDrug CarriersHumansInjections, IntraventricularKaplan-Meier EstimateMacrophagesMiceMice, Inbred BALB CMicroscopy, ConfocalNanoparticlesNeoplasmsPositron-Emission TomographyRAW 264.7 CellsDoxorubicinDrug CarriersSilicon Dioxidecancercell-mediated drug deliverydoxorubicinglioblastomamacrophagesnanoparticles

Identifiers

PMID30368972
PMCPMC6506271
OpenAlexW2896009316

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.